KR102736073B1 - Mat2A의 헤테로바이시클릭 억제제 및 암 치료를 위한 이의 사용 방법 - Google Patents

Mat2A의 헤테로바이시클릭 억제제 및 암 치료를 위한 이의 사용 방법 Download PDF

Info

Publication number
KR102736073B1
KR102736073B1 KR1020207030741A KR20207030741A KR102736073B1 KR 102736073 B1 KR102736073 B1 KR 102736073B1 KR 1020207030741 A KR1020207030741 A KR 1020207030741A KR 20207030741 A KR20207030741 A KR 20207030741A KR 102736073 B1 KR102736073 B1 KR 102736073B1
Authority
KR
South Korea
Prior art keywords
delete delete
carcinoma
cancer
pyrimidin
equiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207030741A
Other languages
English (en)
Korean (ko)
Other versions
KR20200138769A (ko
Inventor
제논 디. 콘테아티스
밍종 리
펭 리우
매튜 메데이로스
사무엘 케이. 레즈닉
지화 수이
제레미 엠. 트라빈스
자네타 포포비치-물러
슈바오 조우
광닝 마
Original Assignee
르 라보레또레 쎄르비에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20200138769A publication Critical patent/KR20200138769A/ko
Application granted granted Critical
Publication of KR102736073B1 publication Critical patent/KR102736073B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020207030741A 2018-03-30 2019-03-28 Mat2A의 헤테로바이시클릭 억제제 및 암 치료를 위한 이의 사용 방법 Active KR102736073B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/081328 2018-03-30
CN2018081328 2018-03-30
PCT/US2019/024645 WO2019191470A1 (en) 2018-03-30 2019-03-28 Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Publications (2)

Publication Number Publication Date
KR20200138769A KR20200138769A (ko) 2020-12-10
KR102736073B1 true KR102736073B1 (ko) 2024-12-02

Family

ID=67439309

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207030741A Active KR102736073B1 (ko) 2018-03-30 2019-03-28 Mat2A의 헤테로바이시클릭 억제제 및 암 치료를 위한 이의 사용 방법

Country Status (21)

Country Link
US (1) US11524960B2 (enExample)
EP (1) EP3774805B1 (enExample)
JP (2) JP7350005B2 (enExample)
KR (1) KR102736073B1 (enExample)
CN (1) CN111936499B (enExample)
AR (1) AR115326A1 (enExample)
AU (1) AU2019243289B2 (enExample)
BR (1) BR112020020104A2 (enExample)
CA (1) CA3094476C (enExample)
EA (1) EA202092320A1 (enExample)
ES (1) ES2973114T3 (enExample)
HU (1) HUE066282T2 (enExample)
IL (1) IL277665B2 (enExample)
MA (1) MA52232A (enExample)
MX (1) MX2020010005A (enExample)
PH (1) PH12020551507A1 (enExample)
PL (1) PL3774805T3 (enExample)
SG (1) SG11202009195WA (enExample)
TW (1) TWI719437B (enExample)
UA (1) UA127059C2 (enExample)
WO (1) WO2019191470A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123395A1 (en) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
LT3902803T (lt) 2018-12-27 2023-04-25 Les Laboratoires Servier Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui
EA202191800A1 (ru) * 2018-12-27 2021-09-13 Ле Лаборатуар Сервье Сас Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак
SG11202112952SA (en) * 2019-05-31 2021-12-30 Servier Lab Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
US20230227409A1 (en) * 2020-06-10 2023-07-20 Ideaya Biosciences, Inc. Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors
WO2021252680A1 (en) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
EP4165040B1 (en) * 2020-06-10 2025-08-27 Ideaya Biosciences, Inc. 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors
US20240208965A1 (en) * 2020-06-10 2024-06-27 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
CN115960098B (zh) * 2020-09-11 2026-04-10 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
CN115916778B (zh) * 2020-09-12 2026-03-20 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
WO2022063128A1 (zh) * 2020-09-24 2022-03-31 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
CN114507231B (zh) * 2020-11-17 2025-06-03 南京再明医药有限公司 内酰胺类化合物及其制备方法
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
US20240124454A1 (en) * 2020-12-31 2024-04-18 Nanjing Zaiming Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2022222911A1 (zh) * 2021-04-19 2022-10-27 武汉人福创新药物研发中心有限公司 嘧啶酮化合物及其用途
CN117412967A (zh) * 2021-06-02 2024-01-16 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a抑制剂
AR127404A1 (es) 2021-10-20 2024-01-17 Insilico Medicine Ip Ltd Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
CN114028572B (zh) * 2021-11-30 2022-11-25 清华大学 Mat2a抑制剂用于治疗哮喘的新应用
CN118414338A (zh) * 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
WO2023125737A1 (en) * 2021-12-29 2023-07-06 Silexon Ai Technology Co., Ltd. Heterocyclic compounds and use thereof
JP2025503186A (ja) * 2022-01-26 2025-01-30 勤浩医▲葯▼（▲蘇▼州）有限公司 Ｍｔａｐ欠失型がん治療用メチオニンアデノシルトランスフェラーゼ２ａ阻害剤
WO2023169554A1 (zh) * 2022-03-11 2023-09-14 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
JP2025521737A (ja) 2022-06-27 2025-07-10 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 三環式化合物およびその使用
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
AU2023361063A1 (en) 2022-10-13 2025-04-17 Hanmi Pharm. Co., Ltd. Novel tricyclic derivative compound and uses thereof
CN121241050A (zh) * 2023-03-06 2025-12-30 甘李药业股份有限公司 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
AU2024302736C1 (en) * 2023-06-14 2026-01-29 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Crystal form of methionine adenosyltransferase 2a heterocyclic inhibitor, preparation method therefor, and use thereof
WO2025000265A1 (en) * 2023-06-28 2025-01-02 Silexon Ai Technology Co., Ltd. Heterocyclic compounds usefull as sos1 inhibitor
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025088571A1 (en) * 2023-10-26 2025-05-01 Astrazeneca Ab Crystalline forms of tead inhibitor
CN117567473B (zh) * 2023-11-09 2025-07-04 中国药科大学 一种靶向同源二聚体的抑制剂及其制备方法与应用
WO2025166260A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025166274A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025166257A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166215A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016064960A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517486A (ja) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
MX2012004846A (es) * 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
MA41551A (fr) * 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2018009544A1 (en) * 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2018039972A1 (en) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
JP6832430B2 (ja) 2016-08-31 2021-02-24 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞代謝過程の阻害剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016064960A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors

Also Published As

Publication number Publication date
TWI719437B (zh) 2021-02-21
US20210115045A1 (en) 2021-04-22
CN111936499B (zh) 2023-09-19
HUE066282T2 (hu) 2024-07-28
PL3774805T3 (pl) 2024-05-06
JP2021519783A (ja) 2021-08-12
AR115326A1 (es) 2020-12-23
CA3094476C (en) 2025-05-06
BR112020020104A2 (pt) 2021-01-26
EP3774805B1 (en) 2024-01-10
CN111936499A (zh) 2020-11-13
IL277665A (en) 2020-11-30
JP2023101762A (ja) 2023-07-21
IL277665B2 (en) 2023-06-01
TW201946629A (zh) 2019-12-16
AU2019243289A1 (en) 2020-09-24
EA202092320A1 (ru) 2021-03-09
WO2019191470A1 (en) 2019-10-03
WO2019191470A8 (en) 2019-12-12
MA52232A (fr) 2021-02-17
CA3094476A1 (en) 2019-10-03
UA127059C2 (uk) 2023-03-29
JP7350005B2 (ja) 2023-09-25
SG11202009195WA (en) 2020-10-29
EP3774805A1 (en) 2021-02-17
PH12020551507A1 (en) 2021-09-13
AU2019243289B2 (en) 2023-01-12
US11524960B2 (en) 2022-12-13
ES2973114T3 (es) 2024-06-18
NZ767697A (en) 2025-02-28
MX2020010005A (es) 2020-10-14
KR20200138769A (ko) 2020-12-10

Similar Documents

Publication Publication Date Title
KR102736073B1 (ko) Mat2A의 헤테로바이시클릭 억제제 및 암 치료를 위한 이의 사용 방법
KR102823567B1 (ko) Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법
AU2020284018A1 (en) Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
KR20220050832A (ko) Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법
HK40049450A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
HK40049450B (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
RU2809987C2 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
EA041815B1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
OA20638A (en) Aza-heterobicyclic inhibitors Of MAT2A and methods of use for treating cancer.
EA046111B1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
HK40061678B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
HK40061678A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201026

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220328

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240223

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241021

PX0701 Decision of registration after re-examination

Patent event date: 20241111

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241126

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241127

End annual number: 3

Start annual number: 1

PG1601 Publication of registration